← Back to patent-cliff list
Brexanolone (extended-release injectable aqueous suspension formulation)
Tier C — Watch / tradeBrexanolone (extended-release injectable aqueous suspension formulation)
Brii Biosciences Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：GABAAR
Indications (approved)：产后抑郁症, Depressive disorder
Regional status
US
Phase II
2023-09-29
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Brexanolone (extended-release injectable aqueous suspension formulation)?
Approved indications include: 产后抑郁症, Depressive disorder.
When does the Brexanolone (extended-release injectable aqueous suspension formulation) patent expire?
No public expiry year is available for Brexanolone (extended-release injectable aqueous suspension formulation) yet; this page updates once verified.
How do I get a quote for Brexanolone (extended-release injectable aqueous suspension formulation) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02